Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil

Trop Med Int Health. 2016 Jun;21(6):692-3. doi: 10.1111/tmi.12697. Epub 2016 Apr 26.

Authors

Sostenes Mistro^{1

2}, Marlon Rodrigues², Lorena Rosa², Marianne Camargo², Roberto Badaró^{1

3}

Affiliations

¹ Program of Post-Graduation in Medicine and Health, Federal University of Bahia, Salvador, Bahia, Brazil.
² Multidisciplinary Institute of Health, Federal University of Bahia, Vitória da Conquista, Bahia, Brazil.
³ Department of Medicine and Diagnosis, Federal University of Bahia, Salvador, Bahia, Brazil.

PMID: 27037644
DOI: 10.1111/tmi.12697

No abstract available

Keywords: Brazil; access to medication; developing countries; leishmaniasis; liposomal amphotericin B; pharmacoeconomics.

Publication types

Editorial

MeSH terms

AIDS-Related Opportunistic Infections / prevention & control
Amphotericin B / therapeutic use*
Antiprotozoal Agents / therapeutic use*
Brazil
Humans
International Cooperation
Leishmaniasis, Visceral / drug therapy*
Leishmaniasis, Visceral / prevention & control
Tropical Medicine*

Substances

Antiprotozoal Agents
liposomal amphotericin B
Amphotericin B